RE:RE:RE:Drug Discovery ExpertAgain, looking at Sutro yesterday showed me that Thera is not undervalued giving the fact they have no published results on humans in oncology and that NASH at this point is more a drag on the SP than anything. I think there is a fear that they will dilute a lot to get cash to go in NASH alone, which would be very risky and long.
I hope for a clear proof of concept in oncology and that as a result, the company will givie up on NASH. This program is too onerous and risky for a company like Thera. They pushed that because they had nothing else and at first they wanted to limit it to HIV NASH. Now it's general NASH which is not in the same league. If they have a clear proof of concept in oncology, they should put all the focus and ressources on that. To do that, they need real and clear proof of concept, not mild results that are unclear.
I think a combination of a real clear proof of concept in oncology plus the news of giving up NASH plans would push the SP. Remember that the news that they would pursue general NASH came as a big surprise giving how expensive it would be. We can say all we want, but they did not convince anybody that NASH would be a slam dunk for them. Yes they have a nice set of undirect data that supports the rationale behind tesamorelin working in this indication, but the cost and duration of the whole thing is prohibibitive in my view. If oncology does not work, they could try it up to the futility test, but if oncology works, why dilute and lose focus?
SPCEO1 wrote: Phase 1a data that inspires hope that TH-1902 and/or some new version of a PDC developed by TH can be a cancer game-changer will go a long way toward helping change the narrative. Unfirtunately, TH itself never seems to be able to consistently put together a narrative that is appealing to investors and thus the lack of interest even though we may be days or weeks away from whoat could be very important news not only for us shareholders but also for many people suffering with certain types of cancer. Hopefully, the new IR officer they eventually hire will be able to break the old mode of thinking at TH which has led the stock to so drammatically underperform its peers for so very long. In my view, TH is now a much better investment opportunity now than it was when we had high hopes for Trogarzo sales (due to pretty intriguing prospects in two huge drug markets - cancer and NASH). But depsite the massive bull market, the company has failed pretty badly in creating an attractive narrative for investors around those opportunities. It has cost us a lot and the entrenched way of thinking about this at TH needs to be tossed out the window.
But we need good phase 1a data to get a new, more favorable narrative started. Without that, a new narrative is not going to have much of a chance in the short term.
Wino115 wrote: It is likely a fairly small community for experienced people like this. I see he worked for the other Belivieu company, AngioChem, that is looking for drugs to work in the brain. Probably known to the UQAM lab guys that came with the Katana acquisition. Looks great on paper!
A real shame the share actually broke that 3 handle it tried for years to get over. This lack of interest, seen through the pathetic volume, has once again reset the price. I'm not that worried and feel we may see an equivalent reaction on the other side since this is clearly year end house cleaning for investors who lost interest and became bored with THTX. The narrative needs to change in the new year.
scarlet1967 wrote: This new recruit this month seems to be related to their oncology program, I think it encouraging despite the depressed valuation for whatever reason (tax loss selling, lack of exposure, little marketing efforts…)to see the company is adding to their scientific team for their oncology program some 9 months after it went into trial phase.
“ Highly experienced Drug Discovery expert with a demonstrated history of working in industry and academia for more than 20 years and a remarkable track record of delivering 10 drug candidates into preclinical and clinical development across various disease areas. Strong professional skills in Medicinal Chemistry for small molecules, biologics (ADCs) and analytical chemistry such as modern applications on liquid chromatography mass spectrometry (LC - MS), matrix-assisted laser desorption/ionization (MALDI) and nuclear magnetic resonance (NMR) technologies.
Skills: Drug Discovery, Medicinal Chemistry, Synthesis (small molecules and ADCs), liquid chromatography mass spectrometry (LC MS), MALDI and nuclear magnetic resonance (NMR) technologies, anti-viral (HIV, HCV and Corona virus).”
Sanjoy Kumar Das, Ph.D. | LinkedIn